RESULTS RECIPIENT PREGNANCY DETAILS PATIENT INFORMATION

WOMENS HEALTH PRACTICE @ NYP Due Date: 11/26/2023 AYESHA HARRIS

Attn: Kelsey Musselman Gestational Age: 24 weeks, 3 days
505 E 70th St Fl 5 Pregnancy Type: Singleton
New York, NY 10021 Patient Weight: Not provided
Phone: (212) 746-3200 Patient Height: Not provided
Fax: (212) 746-8762 Ovum Donor Age: N/A
NPI: 1255866760 NT Ultrasound Date: Not provided
Report Date: 08/17/2023 NT: Not provided
CRL: Not provided
DOB: 03/07/1995
Ethnicity: Mixed or Other
Caucasian
Sample Type: Streck Cell-Free
DNA Blood Tube
Date of Collection: 08/09/2023
Date Received: 08/10/2023
Date Tested: 08/16/2023
Barcode: 31004879811016
Accession ID: 604984186

Prequel® Prenatal Screen NEGATIVE

with AMPLIFY™ technology

ABOUT THIS TEST PANEL DETAILS

The Myriad Prequel Prenatal Screen with AMPLIFY technology Chromosomes 13, 18, 21 + Sex Chromosome Analysis
detects whether a pregnancy is at increased risk for certain
chromosome conditions.

RESULTS SUMMARY

Condition Results Patient-specific Residual Risk*

Trisomy 13 (Patau Syndrome) NEGATIVE < 0.01% (1 in 10,000)

Results consistent with two copies of chromosome 13. Residual Risk

Trisomy 18 NEGATIVE < 0.01% (1 in 10,000)

Results consistent with two copies of chromosome 18. Residual Risk
(Edwards Syndrome)

Trisomy 21 (Down Syndrome) NEGATIVE < 0.01% (1 in 10,000)

Results consistent with two copies of chromosome 21. Residual Risk

Predicted Fetal Sex: Female

Results consistent with two sex chromosomes (XX).

NEXT STEPS

Genetic counseling is available, if desired.

CLINICAL NOTES

* The residual risks provided represent the remaining chance that the pregnancy is affected with the indicated chromosome
aneuploidy in view of a negative result.

This is a screening test; therefore, false positive and false negative results can occur. No irreversible decision should be made based
on these findings only. Clinical correlation with ultrasound findings and history is indicated. If definitive diagnosis is desired, chorionic
villus sampling or amniocentesis is necessary.

Copyright 2023 Myriad Women's Health, Inc. All rights reserved. 180 Kimball Way, South San Francisco, CA 94080 Page 1 of 3
(888) 268-6795 | http://www.myriadwomenshealth.com
 RESULTS RECIPIENT PREGNANCY DETAILS PATIENT INFORMATION
WOMENS HEALTH PRACTICE @ NYP Due Date: 11/26/2023 AYESHA HARRIS
Attn: Kelsey Musselman Gestational Age: 24 weeks, 3 days DOB: 03/07/1995
NPI: 1255866760 Pregnancy Type: Singleton Ethnicity: Mixed or Other
Report Date: 08/17/2023 Caucasian
Barcode: 31004879811016

FETAL FRACTION Fetal fraction is one component of the algorithm used and is combined with other quality metrics to
19.2% determine the aneuploidy screening result.

Methods and limitations

Methodology: Sequencing with fetal chromosome analysis (Assay(s): NIPS v4.0).

Conditions Tested: Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, and Sex Chromosome Analysis.

Sequencing with fetal chromosome analysis

Nucleic acid extraction and DNA sequencing with fetal fraction enhancement are used to detect fetal chromosomal abnormalities. Genome Reference Consortium Human
Build 37(GRCh37)/hg19 is used for alignment. This test is validated to detect fetal aneuploidies, including targeted deletions in chromosomal regions 1p36, 4p16.3, 5p15.2,
15q11.2, and 22q11.2. This test is validated for singleton pregnancies with a gestational age of at least 10 weeks, as estimated by last menstrual period. For twin
pregnancies, analysis is limited to aneuploidy for chromosomes 13, 18 and 21. The content of the report is determined by the test requested.

RESIDUAL RISK AND POSITIVE PREDICTIVE VALUE (PPV)

For trisomy 13, trisomy 18, and Down syndrome, individualized residual risks and PPV are calculated from the test performance and disease prevalence based upon the
provided gestational and patient ages (or age of ovum donor, if available). Monosomy X PPV is calculated from test performance and prevalence based upon the provided
gestational age. Twin PPV and residual risk calculations for trisomy 13, trisomy 18, and Down syndrome, additionally incorporate prevalence of both monozygotic and
dizygotic scenarios, regardless of individual status. When an "aneuploidy detected" result is reported in a twin pregnancy, the status of each individual fetus cannot be
determined. Although predicted fetal sex can be reported in a twin pregnancy, the occurrence of sex chromosome aneuploidies such as monosomy X, XXX, XXY and XYY
cannot be evaluated in twin pregnancies.

PRENATAL TEST PERFORMANCE DATA

Chromosome Sensitivity (95% CI) Specificity (95% CI) Chromosome Sensitivity (95% CI) Specificity (95% CI)

21 99.7% (99.1 - 99.9) 99.96% (99.93 - 99.98) Monosomy X 95.8% (70.3 - 99.5) 99.86% (99.62 - 99.95)

21 (twins) 98.6% (92 - 100) 99.95% (99 - 100) XX 97.6% (94.8 - 99.1) 99.2% (97.2 - 99.9)

18 97.9% (94.9 - 99.1) 99.96% (99.93 - 99.97) XY 99.1% (96.9 - 99.9) 98.9% (96.9 - 99.8)

13 99.0% (65.8 - 100.0) 99.96% (99.93 - 99.98)

XXX/XXY/XYY Other sex aneuploidies will be reported if detected. (Limited data for these less common aneuploidies preclude performance calculations.)

Sex chromosome mosaicism cannot be distinguished by this method (the occurrence of which is <0.3%). Patients with such mosaicism will have a sex chromosome result
reported and will fall into one of six categories (Monosomy X, XXX, XXY, XYY, XX, XY).

1p36 deletion syndrome, 4p16.3 deletion, 5p15.2 deletion, When requested, the listed microdeletions will be reported if detected. (Limited data for these rare
15q11.2 deletion syndrome, 22q11.2 deletion syndrome subchromosomal abnormalities preclude performance calculations.)

When requested, autosomal aneuploidies of chromosomes other than 21, 18, 13 will be reported if
Expanded autosomal aneuploidies
detected. (Limited data for these aneuploidies preclude performance calculations).

Note: the above test performance statistics refer to singleton pregnancies unless otherwise stated.

Limitations
This is a screening test; therefore, false positive and false negative results can occur. Clinical correlation with ultrasound findings and history is indicated. If definitive
diagnosis is desired, chorionic villus sampling or amniocentesis is necessary. Negative results do not fully exclude the presence of any chromosome abnormality, birth defect
or other condition. This test is not intended to identify pregnancies at risk for open neural tube defects.

Copyright 2023 Myriad Women's Health, Inc. All rights reserved. 180 Kimball Way, South San Francisco, CA 94080 Page 2 of 3
(888) 268-6795 | http://www.myriadwomenshealth.com
 RESULTS RECIPIENT PREGNANCY DETAILS PATIENT INFORMATION
WOMENS HEALTH PRACTICE @ NYP Due Date: 11/26/2023 AYESHA HARRIS
Attn: Kelsey Musselman Gestational Age: 24 weeks, 3 days DOB: 03/07/1995
NPI: 1255866760 Pregnancy Type: Singleton Ethnicity: Mixed or Other
Report Date: 08/17/2023 Caucasian
Barcode: 31004879811016

Possible sources of error include sample mix-up, trace contamination, bone marrow transplantation, chimerism or mosaicism, maternal neoplasm, maternal subchromosomal
abnormalities, and technical errors. This test was developed, and its performance characteristics determined by Myriad Women's Health, Inc. It has not been cleared or
approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It
should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to
perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation and should be interpreted in the context of all available clinical
findings. CLIA Number: #05D1102604.

Incidental Findings

Unless otherwise indicated, these results and interpretations are limited to the specific disease panel(s) requested by the ordering healthcare provider. In some cases,
standard data analyses may identify genetic findings beyond the region(s) of interest specified by the test, and such findings may not be reported. These findings may
include fetal and/or maternal genomic variations with major, minor, or no, clinical significance. Occasionally, these findings may be associated with benign or malignant
maternal neoplasms.

If you have questions or would like more information about any of the test methods or limitations, please contact (888) 268-6795.

REFERENCES

• Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet
Gynecol 2012, 119(5):890-901.
• Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound
Obstet Gynecol 2017;50:302-14.
• Gravholt CH, Juul S, Naeraa RW, Hansen J. Prenatal and postnatal prevalence of Turner's syndrome : a registry study. BMJ. 1996;312:16-21.
• Illumina, Inc. Analytical Validation of the verifi® prenatal test: Enhanced Test Performance for Detecting Trisomies 21, 18, and 13 and the Option for Classification of Sex
Chromosome Status. 2012.
• Liao H, Liu S, Wang H. Performance of non-invasive prenatal screening for fetal aneuploidy in twin pregnancies: a meta-analysis. Prenat Diagn. 2017;37: 874-882.
• Rodis JF, Egan JF, Craffey A, Ciarleglio L, Greenstein RM, Scorza WE. Calculated risk of chromosomal abnormalities in twin gestations. Obstet Gynecol. 1990;76:
1037-1041.
• Simpson LL. Twin-twin transfusion syndrome. Am J Obstet Gynecol. Elsevier; 2013;208: 3-18.
• Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70.
• Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH. Maternal age and gestation age-specific risks for chromosomal defects. Fetal Diag Ther 1995;10:356-67.

SENIOR LABORATORY DIRECTOR

Karla R. Bowles, PhD, FACMG, CGMB

Report content approved by Karla Bowles, PhD, FACMG, CGMB on Aug 17, 2023

Copyright 2023 Myriad Women's Health, Inc. All rights reserved. 180 Kimball Way, South San Francisco, CA 94080 Page 3 of 3
(888) 268-6795 | http://www.myriadwomenshealth.com